ArticleFrontiers in public health2026
Molecular transmission network and drug resistance analysis of 404 HIV-1 cases infected through commercial heterosexual contact (2020-2024).
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancing Precision Public Health: an implementation science framework for HIV Cluster Detection and Response driven by molecular epidemiology.Frontiers in public health · 2026Article
- Molecular transmission network analysis of HIV-1 among older adults in Central China: a cross-sectional study in Shaodong City.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HIV/AIDS remains a significant public health challenge. This study aimed to investigate the molecular transmission network and drug resistance characteristics among HIV-1 infected individuals through commercial heterosexual contact in Yubei District which located in a southwest city in China, thereby assessing HIV transmission risks in the region. Methods: Blood samples were collected from newly diagnosed HIV-1 patients in Yubei District in Chongqing city between 2020 and 2024, all of whom acquired the infection through commercial heterosexual contact. The HIV-1 pol region was amplified and sequenced to construct a phylogenetic tree. Drug resistance mutation sites were obtained by comparing with the Stanford Drug Resistance database. A molecular transmission network was constructed using a genetic distance threshold of 1.3%. Univariate and multivariate logistic regression analyses were used to determine potential factors influencing network entry and the formation of large clusters. Results: Among the 404 sequences, CRF07_BC was the predominant genotype (55.9%). The pretreatment drug resistance rate was 4.70% for all cases of commercial heterosexual exposure. Molecular network analysis revealed that 223 sequences (with an entry rate of 55.2%) formed 39 clusters, including 6 large clusters with more than 10 nodes. Multivariate logistic regression models identified age ≥ 60 years, household registration in Yubei District, and CRF85_BC genotype as risk factors for network inclusion and large cluster formation. Additionally, the study identified a transmission cluster with significant geographic aggregation, featuring one female sex worker who posed a high transmission risk. Conclusion: HIV-1 infections transmitted through commercial heterosexual contact exhibit pronounced geographic clustering, with over half of the cases belonging to the CRF07_BC genotype. Although the pretreatment drug resistance prevalence remains low, establishing a sustained resistance surveillance system remains essential. Targeted management and precise interventions are required for identified high-risk transmission networks to effectively curb further spread of HIV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.